CytoDyn to Hold Webcast and Live Q/A on January 13
Post# of 148166
(Total Views: 540)
Posted On: 01/11/2022 4:37:32 PM
CytoDyn to Hold Webcast and Live Q/A on January 13
VANCOUVER, Washington, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, Nitya Ray, Ph.D., Chief Operating Officer and Chief Technology Officer and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations of CytoDyn will host an investment community webcast to discuss and provide updates with regard to NASH data results (350 and 700 mg), Cancer, COVID-19, HIV BLA, and finances of the Company on Thursday, January 13, 2022.
CytoDyn will present for 60 minutes, including live questions and answers.
https://www.cytodyn.com/newsroom/press-releas...january-13
VANCOUVER, Washington, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, Nitya Ray, Ph.D., Chief Operating Officer and Chief Technology Officer and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations of CytoDyn will host an investment community webcast to discuss and provide updates with regard to NASH data results (350 and 700 mg), Cancer, COVID-19, HIV BLA, and finances of the Company on Thursday, January 13, 2022. CytoDyn will present for 60 minutes, including live questions and answers.
https://www.cytodyn.com/newsroom/press-releas...january-13
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.
Scroll down for more posts ▼